Study of efficacy and safety of oral tofacitinib vs azathioprine in the management of chronic actinic dermatitis-An open randomised clinical trial

Krishna Vishwa Vidyapeeth0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•1. Patients with Clinical diagnosis of chronic actinic dermatitis including:
•Actinic Prurigo
•Actinic cheilitis
•Lichenoid photodermatitis
•Photoallergic dermatitis
•Phytophotodermatitis
•Actinic reticuloid
•2. Age group more than 18 years of age.
•3. The patient should have given written consent before the investigations and starting the drug.
•4. The patient should be able and willing and fit, in the view of the investigator, to comply with all study procedures

•A .Patients with acute photodermatitis.
•B. Patients allergic to tofacitinib or azathioprine.
•C. Patient with cardiac diseases or hematological diseases (including angina, coronary artery disease, recent or acute myocardial infarction, pericardial effusion,anemia,coagulation disorders)
•D. Patients with cerebrovascular diseases
•E.Patients with deranged liver and kidney function.
•F. Patients with recent infections.
•G. Patient with positive mantoux test.
•H.Patients with a recent or past history of tuberculosis
•I.Patient with a positive Interferon Gamma Release Assay (IGRA) test.
•J.Patients with a history of acute phototoxic diseases.
•K.Phototoxic rash related to some drug.
•L.Patients with Low Thiopurine Methyl Transferase(TPMT) value ( < 0.5 U). M.Pregnant,lactating or women of child bearing age group with incomplete family. N.Patients with positive HIV,HCV or HbsAg.
•O.Patients having diabetes mellitus.
•P.Patients with any immunocompromised conditions.

发起方

Krishna Vishwa Vidyapeeth